

# Teprotumumab for the Treatment of Active Thyroid Eye

New England Journal of Medicine

382, 341-352

DOI: [10.1056/nejmoa1910434](https://doi.org/10.1056/nejmoa1910434)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Orbital disease in neuro-ophthalmology. <i>Current Opinion in Ophthalmology</i> , 2020, 31, 469-474.	1.3	1
2	Medical and surgical treatment of thyroid eye disease. <i>Internal Medicine Journal</i> , 2022, 52, 14-20.	0.5	7
3	Proposal for Standardization of Primary and Secondary Outcomes in Patients with Active, Moderate-to-Severe Gravesâ€™ Orbitopathy. <i>European Thyroid Journal</i> , 2020, 9, 3-16.	1.2	23
4	Is there a role for insulin-like growth factor inhibition in the treatment of COVID-19-related adult respiratory distress syndrome?. <i>Medical Hypotheses</i> , 2020, 144, 110167.	0.8	22
5	Advances in steroid sparing medical management of active thyroid eye disease. <i>Seminars in Ophthalmology</i> , 2020, 35, 216-223.	0.8	1
6	Teprotumumab Treatment for Thyroid-Associated Ophthalmopathy. <i>European Thyroid Journal</i> , 2020, 9, 31-39.	1.2	5
7	Teprotumumab: a disease modifying treatment for gravesâ€™ orbitopathy. <i>Thyroid Research</i> , 2020, 13, 12.	0.7	8
8	Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101383.	2.2	10
9	Epidemiology, Natural History, Risk Factors, and Prevention of Gravesâ€™ Orbitopathy. <i>Frontiers in Endocrinology</i> , 2020, 11, 615993.	1.5	132
10	Distinctive Features of Orbital Adipose Tissue (OAT) in Gravesâ€™ Orbitopathy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9145.	1.8	9
11	Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease. <i>British Journal of Ophthalmology</i> , 2022, 106, 165-171.	2.1	29
12	Trends in Treatment of Active, Moderate-to-Severe Thyroid Eye Disease in the United States. <i>Journal of the Endocrine Society</i> , 2020, 4, bvaa140.	0.1	8
13	Teprotumumab for the treatment of thyroid eye disease. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 739-743.	1.3	3
15	Differential gene signature in adipose tissue depots of growth hormone transgenic mice. <i>Journal of Neuroendocrinology</i> , 2020, 32, e12893.	1.2	5
16	Prevalence of hyperthyroidism, hypothyroidism, and euthyroidism in thyroid eye disease: a systematic review of the literature. <i>Systematic Reviews</i> , 2020, 9, 201.	2.5	35
17	Management of Graves Thyroidal and Extrathyroidal Disease: An Update. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3704-3720.	1.8	107
19	Integrating Differential Gene Expression Analysis with Perturbagen-Response Signatures May Identify Novel Therapies for Thyroid-Associated Orbitopathy. <i>Translational Vision Science and Technology</i> , 2020, 9, 39.	1.1	2
20	Novel Approaches for Immunosuppression in Gravesâ€™ Hyperthyroidism and Associated Orbitopathy. <i>European Thyroid Journal</i> , 2020, 9, 17-30.	1.2	18

#	ARTICLE	IF	CITATIONS
21	Targeting TSH and IGF-1 Receptors to Treat Thyroid Eye Disease. <i>European Thyroid Journal</i> , 2020, 9, 59-65.	1.2	17
22	Glucocorticoids in Gravesâ€™ orbitopathy: mechanisms of action and clinical application. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2020, 11, 204201882095833.	1.4	12
23	Antioxidant Therapy in Gravesâ€™ Orbitopathy. <i>Frontiers in Endocrinology</i> , 2020, 11, 608733.	1.5	8
24	Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy. <i>Frontiers in Endocrinology</i> , 2020, 11, 610337.	1.5	4
25	Asymmetric Gravesâ€™ Orbitopathy. <i>Frontiers in Endocrinology</i> , 2020, 11, 611845.	1.5	9
26	Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression. <i>Eye</i> , 2021, 35, 2607-2612.	1.1	33
27	Resolution of pretibial myxedema with teprotumumab in a patient with Graves disease. <i>JAAD Case Reports</i> , 2020, 6, 1281-1282.	0.4	15
28	Modulating TSH Receptor Signaling for Therapeutic Benefit. <i>European Thyroid Journal</i> , 2020, 9, 66-77.	1.2	13
29	Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 645-649.	1.9	13
30	Teprotumumab for Active Thyroid Eye Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1958-1960.	13.9	2
31	Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives. <i>Current Eye Research</i> , 2020, 45, 1325-1341.	0.7	28
32	Targeting the IGF-Axis for Cancer Therapy: Development and Validation of an IGF-Trap as a Potential Drug. <i>Cells</i> , 2020, 9, 1098.	1.8	17
33	Differentially expressed circular RNAs in orbital adipose/connective tissue from patients with thyroid-associated ophthalmopathy. <i>Experimental Eye Research</i> , 2020, 196, 108036.	1.2	22
34	Early experience with teprotumumab for chronic thyroid eye disease. <i>American Journal of Ophthalmology Case Reports</i> , 2020, 19, 100744.	0.4	40
35	The Impact of the Pandemic on Otolaryngology Patients With Negative COVIDâ€™19 Status: Commentary and Insights From Orbital Emergencies. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 163, 444-446.	1.1	5
36	Insulin-like Growth Factor-1 and IGF Binding Proteins Predict All-Cause Mortality and Morbidity in Older Adults. <i>Cells</i> , 2020, 9, 1368.	1.8	40
37	Teprotumumab: First Approval. <i>Drugs</i> , 2020, 80, 509-512.	4.9	36
38	Teprotumumab Significantly Improves Active Moderate-to-Severe Thyroid Eye Disease. <i>Clinical Thyroidology</i> , 2020, 32, 114-116.	0.0	0

#	ARTICLE	IF	CITATIONS
39	Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Gravesâ€™ Disease: results of a pilot study. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1759-1768.	1.8	14
40	Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factorâ€™I Receptor Inhibition. <i>Journal of Neuro-Ophthalmology</i> , 2020, 40, 74-83.	0.4	5
41	Shining a light on thyroid eye disease. <i>Nature Reviews Endocrinology</i> , 2020, 16, 259-260.	4.3	3
42	Treatment of moderate-to-severe and active Gravesâ€™ orbitopathy: a step forward from the OPTIC study. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1523-1525.	1.8	5
43	Graded transantral orbital decompression outcomes in stable thyroid eye disease: a series of 47 orbits. <i>Orbit</i> , 2021, 40, 215-221.	0.5	3
44	Non-specific orbital inflammation: Current understanding and unmet needs. <i>Progress in Retinal and Eye Research</i> , 2021, 81, 100885.	7.3	20
45	Dysthyroid optic neuropathy: evaluation and management. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 421-429.	1.8	66
46	Tratamiento de la oftalmopatÃa de Graves. <i>Medicina ClÃnica</i> , 2021, 156, 180-186.	0.3	8
47	Challenges in diagnosing coexisting ocular myasthenia gravis and thyroid eye disease. <i>Muscle and Nerve</i> , 2021, 63, 631-639.	1.0	7
48	Considerations for Use of Immune Checkpoint Inhibitors in Cancer Therapy for Patients with Co-Existing Thyroid Eye Disease. <i>Ophthalmology and Therapy</i> , 2021, 10, 5-12.	1.0	5
49	Teprotumumab for Optic Neuropathy in Thyroid Eye Disease. <i>JAMA Ophthalmology</i> , 2021, 139, 244.	1.4	29
50	Thyroid Eye Disease: Pathogenic Risk Factors. <i>International Ophthalmology Clinics</i> , 2021, 61, 3-20.	0.3	3
51	Disrupting Insulin and IGF Receptor Function in Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 555.	1.8	31
52	MicroRNA-130a Is Elevated in Thyroid Eye Disease and Increases Lipid Accumulation in Fibroblasts Through the Suppression of AMPK. , 2021, 62, 29.		14
54	Antibodies to watch in 2021. <i>MAbs</i> , 2021, 13, 1860476.	2.6	237
55	A pilot study on the use of prednisoloneâ€encapsulated liposomes for the treatment of moderateâ€toâ€severe Gravesâ€™ orbitopathy with reduced systemic steroid exposure. <i>Acta Ophthalmologica</i> , 2021, 99, 797-804.	0.6	4
56	Thyroid eye disease: Redefining its managementâ€”A review. <i>Clinical and Experimental Ophthalmology</i> , 2021, 49, 203-211.	1.3	10
57	A novel CD4+ CTL subtype characterized by chemotaxis and inflammation is involved in the pathogenesis of Gravesâ€™ orbitopathy. <i>Cellular and Molecular Immunology</i> , 2021, 18, 735-745.	4.8	37

#	ARTICLE	IF	CITATIONS
58	Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment. <i>International Ophthalmology</i> , 2021, 41, 1549-1561.	0.6	6
59	Glucocorticoids for Thyroid Eye Disease. <i>International Ophthalmology Clinics</i> , 2021, 61, 63-78.	0.3	3
60	Selenium in the Treatment of Gravesâ€™™ Hyperthyroidism and Eye Disease. <i>Frontiers in Endocrinology</i> , 2020, 11, 608428.	1.5	24
61	Genetic Profiling of Orbital Fibroblasts from Patients with Gravesâ€™™ Orbitopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2176-e2190.	1.8	18
62	Oculoplastics. , 2021, , 141-153.		0
63	Teprotumumab: The First Approved Biologic for Thyroid Eye Disease. <i>International Ophthalmology Clinics</i> , 2021, 61, 53-61.	0.3	4
64	Graves Ophthalmopathy. , 2021, , 261-271.		0
65	Teprotumumab in Clinical Practice: Recommendations and Considerations From the OPTIC Trial Investigators. <i>Journal of Neuro-Ophthalmology</i> , 2021, 41, 461-468.	0.4	19
66	Updates on the understanding and management of thyroid eye disease. <i>Therapeutic Advances in Ophthalmology</i> , 2021, 13, 251584142110277.	0.8	19
67	Teprotumumab and hearing loss: hear the warnings. <i>Orbit</i> , 2021, 40, 355-356.	0.5	8
68	Orbital Surgical Guidelinesâ€™™ Clinical Evaluation. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2021, 82, 129-141.	0.4	0
69	Bilateral dysthyroid compressive optic neuropathy responsive to teprotumumab. <i>European Journal of Ophthalmology</i> , 2022, 32, NP46-NP49.	0.7	14
70	Enrichment of IGF-1R and PPARÎ³ signalling pathways in orbital inflammatory diseases: steps toward understanding pathogenesis. <i>British Journal of Ophthalmology</i> , 2022, 106, 1012-1017.	2.1	2
71	Statins Decrease the Risk of Orbitopathy in Newly Diagnosed Patients with Graves Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1325-1332.	1.8	33
72	Baseline Volumetric T2 Relaxation Time Histogram Analysis: Can It Be Used to Predict the Response to Intravenous Methylprednisolone Therapy in Patients With Thyroid-Associated Ophthalmopathy?. <i>Frontiers in Endocrinology</i> , 2021, 12, 614536.	1.5	7
73	Treatment of Gravesâ€™™ ophthalmopathy. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 180-186.	0.1	1
74	Steroid-Resistant Gravesâ€™™ Orbitopathy Treated with Tocilizumab in Real-World Clinical Practice: A 9-Year Single-Center Experience. <i>Journal of Clinical Medicine</i> , 2021, 10, 706.	1.0	31
75	Best Achievements in Clinical Thyroidology in 2020. <i>Endocrinology and Metabolism</i> , 2021, 36, 30-35.	1.3	3

#	ARTICLE	IF	CITATIONS
76	Orbital inflammatory disorders: new knowledge, future challenges. <i>Current Opinion in Ophthalmology</i> , 2021, 32, 255-261.	1.3	3
77	Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy. <i>Cells</i> , 2021, 10, 383.	1.8	10
78	Improvement of asymmetric thyroid eye disease with teprotumumab. <i>British Journal of Ophthalmology</i> , 2022, 106, 755-759.	2.1	10
79	Thyroid function suppression after initiation of teprotumumab treatment. <i>Endocrine</i> , 2021, 73, 561-562.	1.1	2
80	New-Onset of Inflammatory Bowel Disease in a Patient Treated With Teprotumumab for Thyroid Associated Ophthalmopathy. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2021, 37, e160-e164.	0.4	21
81	Early Experience With the Clinical Use of Teprotumumab in a Heterogenous Thyroid Eye Disease Population. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2021, 37, 583-591.	0.4	29
82	Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1029-1040.	1.6	12
83	Thyroid Eye Disease: Navigating the New Treatment Landscape. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab034.	0.1	14
84	Thyroid Eye Disease, Teprotumumab, and Hearing Loss: An Evolving Role for Otolaryngologists. <i>Otolaryngology - Head and Neck Surgery</i> , 2021, 165, 019459982110042.	1.1	16
85	Nationwide epidemiological approach to identify associations between keratoconus and immune-mediated diseases. <i>British Journal of Ophthalmology</i> , 2022, 106, 1350-1354.	2.1	25
86	Treatment of moderate to severe orbitopathy: Current modalities and perspectives. <i>Annales D'Endocrinologie</i> , 2021, 82, 92-98.	0.6	7
87	Teprotumumab. <i>Ophthalmology</i> , 2021, 128, 1627-1651.	2.5	26
88	Effect of systemic steroid therapy in Gravesâ€™ orbitopathy on regulatory T cells and Th17/Treg ratio. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 2475-2484.	1.8	8
89	A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2021, 394, 839-852.	1.4	7
90	Cytokines as Targets of Novel Therapies for Gravesâ€™ Ophthalmopathy. <i>Frontiers in Endocrinology</i> , 2021, 12, 654473.	1.5	24
91	Graves' orbitopathy: a multidisciplinary approach. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 65, 157-171.	0.4	4
92	Teprotumumab: The Dawn of Therapies in Moderate-to-Severe Thyroid-Associated Ophthalmopathy. <i>Hormone and Metabolic Research</i> , 2021, 53, 211-218.	0.7	1
93	Real-World Efficacy and Safety of Mycophenolate Mofetil in Active Moderate-to-Sight-Threatening Thyroid Eye Disease. <i>Clinical Ophthalmology</i> , 2021, Volume 15, 1921-1932.	0.9	16

#	ARTICLE	IF	CITATIONS
94	Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease. <i>BMJ Case Reports</i> , 2021, 14, e242153.	0.2	24
95	Teprotumumab for Dysthyroid Optic Neuropathy: Early Response to Therapy. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2021, 37, S157-S160.	0.4	31
97	A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease. <i>American Journal of Ophthalmology Case Reports</i> , 2021, 22, 101069.	0.4	16
98	The knowns and unknowns of teprotumumab for thyroid eye disease. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 323-325.	5.5	2
99	Current Management of Thyroid Eye Disease. <i>Current Treatment Options in Neurology</i> , 2021, 23, 1.	0.7	1
100	Teprotumumab for chronic thyroid eye disease. <i>Orbit</i> , 2022, 41, 539-546.	0.5	27
101	Teprotumumab for thyroid eye disease: early response is not required for benefit. <i>Eye</i> , 2021, , .	1.1	1
102	Wnt signalling inhibits adipogenesis in orbital fibroblasts from patients with Gravesâ€™ orbitopathy. <i>British Journal of Ophthalmology</i> , 2022, 106, 1019-1027.	2.1	6
103	Visual Recovery of Dysthyroid Optic Neuropathy With Teprotumumab. <i>Journal of Neuro-Ophthalmology</i> , 2022, 42, e491-e493.	0.4	8
104	Teprotumumab for the treatment of mild compressive optic neuropathy in thyroid eye disease: A report of two cases. <i>American Journal of Ophthalmology Case Reports</i> , 2021, 22, 101075.	0.4	16
105	Insulin-Like Growth Factor Pathway and the Thyroid. <i>Frontiers in Endocrinology</i> , 2021, 12, 653627.	1.5	29
106	Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 360-372.	5.5	91
107	Teprotumumab and Hearing Loss: Case Series and Proposal for Audiologic Monitoring. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2022, 38, 73-78.	0.4	30
108	Teprotumumab and Hyperglycemia Guidelines to Monitor for Hyperglycemia in Teprotumumab. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2021, 37, 393-393.	0.4	11
109	Teprotumumab Improves the Clinical Course of Thyroid Eye Disease Across Multiple Subgroups of Patients with Durable Responses. <i>Clinical Thyroidology</i> , 2021, 33, 312-315.	0.0	0
110	The 2021 European Group on Gravesâ€™ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Gravesâ€™ orbitopathy. <i>European Journal of Endocrinology</i> , 2021, 185, G43-G67.	1.9	362
111	Tocilizumab for the Management of Thyroid-Associated Orbitopathy. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2022, 38, 188-192.	0.4	6
112	Teprotumumab for the treatment of chronic thyroid eye disease. <i>Eye</i> , 2022, 36, 1553-1559.	1.1	41

#	ARTICLE	IF	CITATIONS
113	Transcriptomic Profiling of Control and Thyroid-Associated Orbitopathy (TAO) Orbital Fat and TAO Orbital Fibroblasts Undergoing Adipogenesis. , 2021, 62, 24.		12
114	Recent advances in thyroid eye disease: An overview. IP International Journal of Ocular Oncology and Oculoplasty, 2021, 7, 117-130.	0.0	2
115	Ototoxicity and Teprotumumab. Annals of Otology, Rhinology and Laryngology, 2022, 131, 910-913.	0.6	10
116	Thyroid-related ophthalmopathy development in concurrence with growth hormone administration. BMC Endocrine Disorders, 2021, 21, 168.	0.9	3
117	A Perspective on the Current Role of Teprotumumab in Treatment of Thyroid Eye Disease. Ophthalmology, 2021, 128, 1125-1128.	2.5	8
118	Histone Deacetylase 4 Controls Extracellular Matrix Production in Orbital Fibroblasts from Graves' Ophthalmopathy Patients. Thyroid, 2021, 31, 1566-1576.	2.4	4
119	2021 update on thyroid-associated ophthalmopathy. Journal of Endocrinological Investigation, 2022, 45, 235-259.	1.8	44
120	18 F-FDG-PET/MRI in patients with Gravesâ€™ orbitopathy.. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 3107-3117.	1.0	7
121	Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: A multicenter study. American Journal of Ophthalmology Case Reports, 2021, 23, 101111.	0.4	29
122	Overview of Graves Ophthalmopathy Literature From 1999 to 2019: Bibliometric Analysis. Interactive Journal of Medical Research, 2021, 10, e24831.	0.6	4
123	Thinking inside the box: Current insights into targeting orbital tissue remodeling and inflammation in thyroid eye disease. Survey of Ophthalmology, 2022, 67, 858-874.	1.7	3
124	Effect of Pirfenidone on TGF-Î²1-Induced Myofibroblast Differentiation and Extracellular Matrix Homeostasis of Human Orbital Fibroblasts in Gravesâ€™ Ophthalmopathy. Biomolecules, 2021, 11, 1424.	1.8	10
125	A systematic review of euthyroid Graves' disease (Review). Experimental and Therapeutic Medicine, 2021, 22, 1346.	0.8	6
126	Bony Orbital Surgery for Graves' Ophthalmopathy. Facial Plastic Surgery, 2021, 37, 692-697.	0.5	2
127	Audiology findings in patients with teprotumumab associated otologic symptoms. American Journal of Ophthalmology Case Reports, 2021, 24, 101202.	0.4	8
128	Graves' Orbitopathy: Current Concepts for Medical Treatment. Klinische Monatsblätter Fur Augenheilkunde, 2021, 238, 24-32.	0.3	5
129	Managing the Esthetic Patient With Thyroid Eye Disease. International Ophthalmology Clinics, 2021, 61, 161-173.	0.3	1
130	Challenges of Managing Strabismus in Thyroid Eye Disease. International Ophthalmology Clinics, 2021, 61, 107-125.	0.3	2



#	ARTICLE	IF	CITATIONS
131	Optic neuropathy and diplopia from thyroid eye disease: update on pathophysiology and treatment. <i>Current Opinion in Neurology</i> , 2021, 34, 116-121.	1.8	13
132	Slit2 Regulation of Hyaluronan and Cytokine Synthesis in Fibrocytes in Thyroid-associated Ophthalmopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1907-1908.	1.8	1
133	Circulating Exosomes From Patients With Gravesâ€™ Disease Induce an Inflammatory Immune Response. <i>Endocrinology</i> , 2021, 162, .	1.4	10
134	Current Knowledge on Gravesâ€™ Orbitopathy. <i>Journal of Clinical Medicine</i> , 2021, 10, 16.	1.0	26
135	Medical management of thyroid eye disease â€“ A paradigm shift. <i>Indian Journal of Ophthalmology</i> , 2020, 68, 1515.	0.5	2
136	Progress in the pathogenesis of thyroid-associated ophthalmopathy and new drug development. <i>Taiwan Journal of Ophthalmology</i> , 2020, 10, 174.	0.3	8
137	Therapeutic Effect of Î±-MSH in Primary Cultured Orbital Fibroblasts Obtained from Patients with Thyroid Eye Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11225.	1.8	3
138	Disulfiram Exerts Antiadipogenic, Anti-Inflammatory, and Antifibrotic Therapeutic Effects in an <i>In Vitro</i> Model of Graves' Orbitopathy. <i>Thyroid</i> , 2022, 32, 294-305.	2.4	7
140	Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment. <i>Ophthalmology</i> , 2022, 129, 438-449.	2.5	64
141	The roles of sex and gender in womenâ€™s eye health disparities in the United States. <i>Biology of Sex Differences</i> , 2021, 12, 57.	1.8	16
142	Role of the mononuclear cell infiltrate in Gravesâ€™ orbitopathy (GO): results of a large cohort study. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 563-572.	1.8	9
143	Rifle Blast Exacerbating Hearing Loss in a Patient Treated With Teprotumumab for Thyroid Eye Disease. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2021, Publish Ahead of Print, .	0.4	7
144	Echographic Assessment of Extraocular Muscle Response to Teprotumumab. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2022, 38, 336-339.	0.4	8
145	An Interesting Case of Euthyroid Gravesâ€™ Ophthalmopathy, With Negative Thyroid-Stimulating Hormone Receptor Antibodies. <i>Cureus</i> , 2021, 13, e19015.	0.2	0
147	Precision Medicine in Gravesâ€™ Disease and Ophthalmopathy. <i>Frontiers in Pharmacology</i> , 2021, 12, 754386.	1.6	13
148	How suitable is intravenous tocilizumab for the treatment of Gravesâ€™ ophthalmopathy?. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 1151-1153.	1.3	2
149	Thyroid Eye Disease. , 2020, , 1-21.		0
151	Thyroid Gland Signs. , 2020, , 27-50.		0

#	ARTICLE	IF	CITATIONS
152	Commentary: Thyroid eye disease in India: A wake-up call?. Indian Journal of Ophthalmology, 2020, 68, 1614.	0.5	0
154	Facial and Eyelid Changes in Thyroid Eye Disease Are Reversed by Teprotumumab. Plastic and Reconstructive Surgery - Global Open, 2021, 9, e3809.	0.3	10
155	Ocular manifestations of endocrine disorders. Australasian journal of optometry, The, 2021, , 1-12.	0.6	4
156	Inhibition of Fibrotic Contraction by Sirolimus (Rapamycin) in an Ex Vivo Model of Thyroid Eye Disease. Ophthalmic Plastic and Reconstructive Surgery, 2021, 37, 366-371.	0.4	4
157	New Medical Device and Therapeutic Approvals in Otolaryngology: State of the Art Review 2020. OTO Open, 2021, 5, 2473974X211057035.	0.6	6
158	Characteristics of Diabetic and Nondiabetic Patients With Thyroid Eye Disease in the United States: A Claims-Based Analysis. Endocrine Practice, 2022, 28, 159-164.	1.1	6
159	Year in Thyroidologyâ€™Recent Developments and Future Challenges: Clinical Science Review. Thyroid, 2021, , .	2.4	1
160	The risk factors for Gravesâ€™ ophthalmopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260, 1043-1054.	1.0	15
161	Inhibition of TSH/IGF-1 receptor crosstalk by Teprotumumab as a treatment modality of Thyroid Eye Disease. Journal of Clinical Endocrinology and Metabolism, 2021, , .	1.8	9
162	Sensorineural Hearing Loss After Teprotumumab Therapy for Thyroid Eye Disease: A Case Report. Otolology and Neurotology, 2022, 43, e148-e152.	0.7	13
163	Efficacy and Safety of Teprotumumab in Thyroid Eye Disease. Therapeutics and Clinical Risk Management, 2021, Volume 17, 1219-1230.	0.9	10
164	Infusion Center Guidelines for Teprotumumab Infusions: Informed Consent, Safety, and Management of Side Effects. Journal of Infusion Nursing, 2021, 44, 331-338.	1.2	2
165	Isolation and characterisation of gravesâ€™ disease-specific extracellular vesicles from tissue maintained on a bespoke microfluidic device. Organs-on-a-Chip, 2021, 3, 100011.	1.8	4
167	Targeting fibrocytes in autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	4
169	A Novel Case of Hyperglycemic Hyperosmolar State After the Use of Teprotumumab in a Patient With Thyroid Eye Disease. AACCE Clinical Case Reports, 2022, 8, 148-149.	0.4	12
170	Thyroid eye disease: From pathogenesis to targeted therapies. Taiwan Journal of Ophthalmology, 2022, 12, 3.	0.3	9
171	Effects of teprotumumab on patients with long-standing, active thyroid eye disease. American Journal of Ophthalmology Case Reports, 2022, 26, 101348.	0.4	3
172	Management of eyelid retraction related to thyroid eye disease. Taiwan Journal of Ophthalmology, 2022, 12, 12.	0.3	6

#	ARTICLE	IF	CITATIONS
173	Ocular surface disease in thyroid eye disease: A narrative review. <i>Ocular Surface</i> , 2022, 24, 67-73.	2.2	14
174	Retinal Surface Macrophage Changes in Thyroid Eye Disease before and after Treatment with Teprotumumab. <i>Case Reports in Ophthalmological Medicine</i> , 2022, 2022, 1-5.	0.3	2
175	Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	20
176	Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition. <i>Thyroid</i> , 2022, 32, 429-439.	2.4	6
177	Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease. <i>JAMA Ophthalmology</i> , 2022, 140, 328.	1.4	29
178	Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease. <i>American Journal of Ophthalmology</i> , 2022, 240, 1-13.	1.7	27
179	Teprotumumab vs Intravenous Methylprednisolone for Thyroid Eye Disease. <i>JAMA Ophthalmology</i> , 2022, 140, 335.	1.4	2
180	It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, S1-S12.	1.8	17
181	Clinical profile of 80-year-old and older thyroid eye disease patients. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2022, , .	1.0	0
182	A Paradigm Shift in the Management of Thyroid Eye Disease How Teprotumumab Has Changed the Therapeutic Interface. <i>Journal of Neuro-Ophthalmology</i> , 2022, 42, 26-34.	0.4	1
183	Insights into Current Management Strategies for Dysthyroid Optic Neuropathy: A Review. <i>Clinical Ophthalmology</i> , 2022, Volume 16, 841-850.	0.9	13
184	The Role of Insulin-like Growth Factor-1 and Its Receptor in the Eye: A Review and Implications for IGF-1R Inhibition. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2023, 39, 4-12.	0.4	5
185	Insights Into Ferroptosis: Targeting Glycolysis to Treat Gravesâ€™ Orbitopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1994-2003.	1.8	4
186	Extraocular Muscle Enlargement in Growth Hormoneâ€“Secreting Pituitary Adenomas. <i>American Journal of Neuroradiology</i> , 2022, 43, 597-602.	1.2	3
187	Thyroid dermopathy responds to teprotumumab therapy. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2022, 2022, .	0.2	2
188	Identification of tRNA-Related Fragments and Their Potential Regulatory Effects in Thyroid-Associated Ophthalmopathy. <i>Frontiers in Genetics</i> , 2022, 13, 878405.	1.1	1
189	Teprotumumab in advanced reactivated thyroid eye disease. <i>American Journal of Ophthalmology Case Reports</i> , 2022, 26, 101484.	0.4	9
190	Retinal nerve fiber layer and ganglion cell complex thickness as a diagnostic tool in early stage dysthyroid optic neuropathy. <i>European Journal of Ophthalmology</i> , 2021, , 112067212110620.	0.7	8

#	ARTICLE	IF	CITATIONS
191	Long-term outcomes in corticosteroid-refractory Graves' orbitopathy treated with tocilizumab. <i>Clinical Endocrinology</i> , 2022, 97, 363-370.	1.2	7
192	Comparative effectiveness of different treatment modalities for active, moderate-to-severe Graves' orbitopathy: a systematic review and network meta-analysis. <i>Acta Ophthalmologica</i> , 2022, 100, .	0.6	3
193	Successful Treatment of Bilateral Compressive Optic Neuropathy With Teprotumumab. <i>Journal of Neuro-Ophthalmology</i> , 2023, 43, e209-e210.	0.4	1
194	Pediatric Graves' orbitopathy: a multicentre study. <i>Acta Ophthalmologica</i> , 2022, 100, .	0.6	5
195	Teprotumumab-associated chronic hearing loss screening and proposed treatments. <i>BMJ Case Reports</i> , 2022, 15, e248335.	0.2	9
196	Ophthalmic Surgery for Graves' Orbitopathy and Quality of Life. <i>Clinical Thyroidology</i> , 2022, 34, 150-152.	0.0	0
197	Teprotumumab for Graves' orbitopathy and ototoxicity: moving problems from eyes to ears?. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 1455-1457.	1.8	22
198	Drug safety in thyroid eye disease – a systematic review. <i>Expert Opinion on Drug Safety</i> , 2022, , .	1.0	1
199	Thyroid Eye Disease. , 2022, , 5111-5131.		0
200	Pathophysiology of autoimmune orbital diseases and target therapy for orbital inflammatory and neoplastic diseases. , 2022, , 105-120.		0
201	Editorial: Mechanisms and Novel Therapies in Graves' Orbitopathy: Current Update. <i>Frontiers in Endocrinology</i> , 2022, 13, 902591.	1.5	0
202	The Effect of Teprotumumab on Eyelid Position in Patients with Thyroid Eye Disease. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2022, 10, e4287.	0.3	2
203	Audiologic Demonstration of Ototoxicity From Teprotumumab Treatment in a Patient With Thyroid Eye Disease. <i>OTO Open</i> , 2022, 6, 2473974X221097097.	0.6	3
204	Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series. <i>Journal of Medical Case Reports</i> , 2022, 16, 195.	0.4	0
205	2022 Update on Clinical Management of Graves Disease and Thyroid Eye Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2022, 51, 287-304.	1.2	23
206	Teprotumumab, a Human Monoclonal Antibody Insulin-like Growth Factor-1 Receptor Inhibitor for Thyroid Eye Disease. <i>Clinical Nurse Specialist</i> , 2022, 36, 134-137.	0.3	0
207	Disulfiram Exerts Antifibrotic and Anti-Inflammatory Therapeutic Effects on Perimysial Orbital Fibroblasts in Graves' Orbitopathy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5261.	1.8	6
208	Dihydroartemisinin Exerts Antifibrotic and Anti-Inflammatory Effects in Graves' Ophthalmopathy by Targeting Orbital Fibroblasts. <i>Frontiers in Endocrinology</i> , 2022, 13, .	1.5	3

#	ARTICLE	IF	CITATIONS
209	Nationwide Incidence of Thyroid Eye Disease and Cumulative Incidence of Strabismus and Surgical Interventions in Denmark. <i>JAMA Ophthalmology</i> , 2022, 140, 667.	1.4	7
210	Hormonal Crosstalk Between Thyroid and Breast Cancer. <i>Endocrinology</i> , 2022, 163, .	1.4	11
211	Current concepts regarding Gravesâ€™ orbitopathy. <i>Journal of Internal Medicine</i> , 2022, 292, 692-716.	2.7	37
212	Reply to Letter to the Editor by Dr. Terry J. Smith regarding teprotumumab and ototoxicity. <i>Journal of Endocrinological Investigation</i> , 0, , .	1.8	4
213	Advances in the Treatment of Thyroid Eye Disease Associated Extraocular Muscle Myopathy and Optic Neuropathy. <i>Current Neurology and Neuroscience Reports</i> , 0, , .	2.0	1
214	Mathematical Modeling of Free Thyroxine Concentrations During Methimazole Treatment for Gravesâ€™ Disease: Development and Validation of a Computer-Aided Thyroid Treatment Method. <i>Frontiers in Endocrinology</i> , 2022, 13, .	1.5	1
215	Letter to the editor regarding Bartalena et al. 2022. <i>Journal of Endocrinological Investigation</i> , 0, , .	1.8	1
216	Rituximab for thyroid-associated ophthalmopathy. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	2
217	Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management. <i>Indian Journal of Ophthalmology</i> , 2022, 70, 2335.	0.5	6
218	Teprotumumab. <i>Advances in Ophthalmology and Optometry</i> , 2022, , .	0.3	0
219	Sirolimus as a second-line treatment for Gravesâ€™ orbitopathy. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 2171-2180.	1.8	10
220	Teprotumumab Divergently Alters Fibrocyte Gene Expression: Implications for Thyroid-associated Ophthalmopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e4037-e4047.	1.8	2
221	Methotrexate plus reduced or full-dose glucocorticoids for the treatment of active, moderate-to-severe Graves' orbitopathy. <i>European Thyroid Journal</i> , 2022, , .	1.2	1
223	Future Projections in Thyroid Eye Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, S47-S56.	1.8	16
224	Measuring Health-Related Quality of Life in Thyroid Eye Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, S27-S35.	1.8	2
225	Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, S36-S46.	1.8	7
226	Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, S13-S26.	1.8	5
227	Bone marrow fibrocytes: villain or white knight in thyroid-associated ophthalmopathy?. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 0, Publish Ahead of Print, .	1.2	1

#	ARTICLE	IF	CITATIONS
228	Likelihood ratio interpretation of the relative risk. <i>BMJ Evidence-Based Medicine</i> , 2023, 28, 241-243.	1.7	3
229	Differential effects of teprotumumab treatment based on fat-to-muscle ratio in patients with thyroid eye disease. <i>Orbit</i> , 0, , 1-8.	0.5	3
230	Effect of teprotumumab on intraocular pressure in thyroid-associated ophthalmopathy. <i>Taiwan Journal of Ophthalmology</i> , 2022, 12, 325.	0.3	0
231	IGF1R signalling is a guardian of self-tolerance restricting autoantibody production. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
232	Current insights of applying MRI in Gravesâ€™ ophthalmopathy. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	4
233	Outcomes of Patients With Thyroid Eye Disease Partially Treated With Teprotumumab. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2023, 39, 150-155.	0.4	5
234	A Multicenter, Single-Blind, Case-Control, Immunohistochemical Study of Orbital Tissue in Thyroid Eye Disease. <i>Thyroid</i> , 2022, 32, 1547-1558.	2.4	5
235	The correlation of the neutrophilâ€“lymphocyte ratio to clinical and imaging parameters in patients with thyroid eye disease. <i>Endocrine Connections</i> , 2022, 11, .	0.8	1
236	Potential Therapeutic Activity of Berberine in Thyroid-Associated Ophthalmopathy: Inhibitory Effects on Tissue Remodeling in Orbital Fibroblasts. , 2022, 63, 6.		4
237	Teprotumumab-Related Hyperglycemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 858-864.	1.8	13
238	Novel Insights into Pathophysiology of Orbital Inflammatory Diseases and Progression to Orbital Lymphoma by Pathway Enrichment Analysis. <i>Life</i> , 2022, 12, 1660.	1.1	1
240	Role of teprotumumab in the treatment of active moderate-to-severe Gravesâ€™ orbitopathy. <i>European Thyroid Journal</i> , 2022, 11, .	1.2	3
241	Recent advances in graves ophthalmopathy medical therapy: a comprehensive literature review. <i>International Ophthalmology</i> , 2023, 43, 1437-1449.	0.6	1
242	New Onset or Deterioration of Thyroid Eye Disease After mRNA SARS-CoV-2 Vaccines: Report of 2 Cases and Literature Review. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 979-985.	1.8	10
243	Impact of Definitive Surgery for Graves' Disease on Adolescent Disease-Specific Quality of Life and Psychosocial Functioning. <i>Thyroid</i> , 2022, 32, 1519-1528.	2.4	3
244	Rituximab in the treatment of Gravesâ€™ orbitopathy: latest updates and perspectives. <i>Endocrine Connections</i> , 2022, 11, .	0.8	4
245	Using 24-h intraocular pressure-related patterns to identify open-angle glaucoma in thyroid eye disease. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 0, , .	1.0	0
246	Long-term management of Graves disease: a narrative review. , 2023, 40, 12-22.		4

#	ARTICLE	IF	CITATIONS
247	Insights Into the Role of DNA Methylation and Gene Expression in Graves Orbitopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, e160-e168.	1.8	3
248	Year in Thyroidology: Clinical Science (2021-2022). <i>Thyroid</i> , 0, , .	2.4	0
249	Graves' disease complicated by concurrent thyroid eye disease and pretibial myxedema successfully treated with teprotumumab. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, .	0.2	2
250	Progress on the application of growth factor-related drugs in ophthalmology. <i>Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical Sciences</i> , 2022, 51, 626-633.	0.1	0
251	Teprotumumab: A Review in Thyroid Eye Disease. <i>Drugs</i> , 2022, 82, 1663-1670.	4.9	4
253	Metformin Attenuates Inflammation and Fibrosis in Thyroid-Associated Ophthalmopathy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15508.	1.8	3
254	Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association. <i>Thyroid</i> , 2022, 32, 1439-1470.	2.4	36
255	Thyroid Eye Disease. <i>Life</i> , 2022, 12, 2084.	1.1	4
256	Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association. <i>European Thyroid Journal</i> , 2022, 11, .	1.2	19
257	Suppression of Insulin Receptor Substrate 1 Inhibits Breast Cancer Growth In Vitro and in Female Athymic Mice. <i>Endocrinology</i> , 2023, 164, .	1.4	2
258	A rare case of severe bilateral Gravesâ€™ orbitopathy involving an anophthalmic socket. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2023, 2023, .	0.2	0
259	Nonneurologic causes of binocular diplopia for the neurologist. <i>Current Opinion in Neurology</i> , 2023, 36, 26-35.	1.8	0
260	Rapamycin improves Gravesâ€™ orbitopathy by suppressing CD4+ cytotoxic T lymphocytes. <i>JCI Insight</i> , 2023, 8, .	2.3	8
261	Utility Assessment of Moderate to Severe Thyroid Eye Disease Health States. <i>JAMA Ophthalmology</i> , 2023, 141, 159.	1.4	7
262	Prospective Assessment of Otolgic Adverse Events due to Teprotumumab: Preliminary Results. <i>Otolaryngology - Head and Neck Surgery</i> , 2023, 168, 1164-1169.	1.1	3
263	Observation study of using a small dose of rituximab treatment for thyroid-associated ophthalmopathy in seven Chinese patients: One pilot study. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	1
264	Teprotumumab for the treatment of thyroid eye disease. <i>Expert Opinion on Biological Therapy</i> , 2023, 23, 123-131.	1.4	1
265	A 46-Year-Old Woman with a 4-Year History of Graves Disease, with Severe Corticosteroid-Unresponsive Thyroid Eye Disease, Successfully Treated with Tocilizumab. <i>American Journal of Case Reports</i> , 0, 24, .	0.3	2



#	ARTICLE	IF	CITATIONS
266	A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves's™ orbitopathy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
267	Monoclonal Antibodies for the Treatment of Graves Orbitopathy: Precision Medicine?. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2023, 39, 307-315.	0.4	1
269	Change in lacrimal gland volume and aqueous tear production following treatment with teprotumumab. <i>Clinical and Experimental Ophthalmology</i> , 2023, 51, 339-348.	1.3	3
271	Endocrinology of Taste with Aging. <i>Endocrinology and Metabolism Clinics of North America</i> , 2023, 52, 295-315.	1.2	1
272	Development and application of animal models to study thyroid-associated ophthalmopathy. <i>Experimental Eye Research</i> , 2023, 230, 109436.	1.2	0
273	Diffusion-Weighted Imaging of the Orbit: A Case Series and Systematic Review. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2023, 39, 407-418.	0.4	1
274	Application of Multiparameter Quantitative Magnetic Resonance Imaging in the Evaluation of Graves' Ophthalmopathy. <i>Journal of Magnetic Resonance Imaging</i> , 0, , .	1.9	1
275	Dysthyroid optic neuropathy: emerging treatment strategies. <i>Journal of Endocrinological Investigation</i> , 2023, 46, 1305-1316.	1.8	5
276	Early response to intravenous methylprednisolone therapy for restrictive myopathy in patients with thyroid eye disease. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 0, , .	1.0	0
277	Reduction in Extraocular Muscle Cross-sectional Area and Correlation With Extraocular Motility and Diplopia Following Teprotumumab for Thyroid Eye Disease. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 0, Publish Ahead of Print, .	0.4	0
278	Approved Protein Therapeutics and Their Biochemical Targets. , 2023, , 199-232.		0
280	Reduction of Teprotumumab-Induced Hearing Loss With Comparable Efficacy Using Half-Dose Therapy. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 0, Publish Ahead of Print, .	0.4	1
281	Chemokines in thyroid autoimmunity. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2023, 37, 101773.	2.2	9
282	Effects of Smoking on Outcomes of Thyroid Eye Disease Treated with Teprotumumab: A Retrospective Cohort Study. <i>Kansas Journal of Medicine</i> , 2023, 16, 62-64.	0.1	3
283	Inflammatory eye disease for rheumatologists. <i>Current Opinion in Rheumatology</i> , 2023, 35, 201-212.	2.0	0
284	Pathogenesis of Thyroid Eye Disease. <i>International Ophthalmology Clinics</i> , 2023, 63, 65-80.	0.3	0
285	Medical Management of Thyroid Eye Disease. <i>International Ophthalmology Clinics</i> , 2023, 63, 81-89.	0.3	0
286	Factors Predicting Long-term Outcome and the Need for Surgery in Graves Orbitopathy: Extended Follow-up From the CIRTED Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 0, , .	1.8	2



#	ARTICLE	IF	CITATIONS
287	Inter-observer Variability of Clinical Activity Score: Assessments in Patients With Thyroid Eye Disease. American Journal of Ophthalmology, 2023, 252, 94-100.	1.7	1
289	The Adverse Effects Profile of Teprotumumab. Journal of Clinical Endocrinology and Metabolism, 2023, 108, e654-e662.	1.8	5
296	Application of approved and marketed products of monoclonal antibody therapies. , 2023, , 287-327.		0
314	Editorial: News in Gravesâ€™ orbitopathy: patients management and treatments. Frontiers in Endocrinology, 0, 14, .	1.5	0
334	Understanding the clinical and molecular basis of thyroid orbitopathy: a review of recent evidence. Hormones, 2024, 23, 25-34.	0.9	1
355	Medical Management of Gravesâ€™ Orbitopathy. , 2023, , 287-293.		0
356	Diagnosis of Gravesâ€™ Orbitopathy. , 2023, , 271-277.		0